NTI receives Small Business Innovative Research (SBIR) grant funding from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) to develop a multiplexed autoantibody and microRNA biomarker-based next-generation test for Type 1 Diabetes (T1D), previously known as juvenile diabetes, in order to better assist in establishing early diagnosis of T1D, refine prognosis, guide management, target treatment, and improve patient outcome.